The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.

Jeremy ThomasA M HanbyN RussellG van TienhovenK RiddleN AndersonD A CameronJ M S BartlettT PiperC CunninghamP CanneyI H Kunklernull null

Published in: Breast cancer research and treatment (2017)

These data have important implications for the design, powering and interpretation of outcomes from this and future clinical trials. If critical pathology criteria are determinants for trial entry, serious consideration should be given to up-front central pathology review.

Keyphrases

clinical trial
phase ii
phase iii
study protocol
open label
double blind
big data
early stage
electronic health record
randomized controlled trial
placebo controlled
locally advanced
current status
artificial intelligence
deep learning
rectal cancer